Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Teva Pharmaceutical Industries ADR (NY: TEVA )

16.99 -0.55 (-3.14%)
Official Closing Price Updated: 7:00 PM EDT, Aug 2, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 12,080,649
Open 17.30
Bid (Size) 16.12 (2)
Ask (Size) 17.42 (1)
Prev. Close 17.54
Today's Range 16.72 - 17.30
52wk Range 8.055 - 18.02
Shares Outstanding 1,110,352,397
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
What Are the Hottest Biotech Stocks Right Now? 3 Top Picks.
Figuring out the hottest biotech stocks can be as simple as looking at the most traded stocks by volume in the last 24 hours. 
Via InvestorPlace
Tech Stocks On Track For Best Session In 5 Months Ahead Of Fed Meeting; Small Caps Target Highest Close Since January 2022: What's Driving Markets Wednesday?
Tech stocks soared to their best session in five months on Wednesday, ahead of the highly anticipated Federal Open Market Committee (FOMC) meeting. 
Via Benzinga
Topics Economy
Exposures Interest Rates

Performance

YTD
+59.23%
+59.23%
1 Month
+3.60%
+3.60%
3 Month
+20.84%
+20.84%
6 Month
+37.24%
+37.24%
1 Year
+76.43%
+76.43%

More News

Read More
Apple, Amazon, Microsoft, Meta Lead The Charge As Investors Bank On Tech Cheer For Rally's Reacceleration: Week Ahead In Earnings
Via Benzinga
Topics Economy
Exposures Interest Rates
$100 Invested In This Stock 5 Years Ago Would Be Worth $200 Today
Via Benzinga
Breaking Down Teva Pharmaceutical Indus: 5 Analysts Share Their Views
Via Benzinga
Match Group Posts Upbeat Sales, Joins Modine Manufacturing, Scotts Miracle-Gro, NVIDIA And Other Big Stocks Moving Higher On Wednesday
Via Benzinga
Teva Pharmaceutical Industries (TEVA) Q2 2024 Earnings Call Transcript
Via The Motley Fool
Topics Earnings
Exposures Financial
Teva Beats Q2 Estimates, Raises Annual Outlook On Strong Generic, Austedo Sales
Via Benzinga
Teva Pharma Flirts With Breakout As Generic Drugs Drive Beat-And-Raise
Via Investor's Business Daily
Teva Announces Strong Growth in Second Quarter Revenues mainly driven by Generics Products in All Regions and AUSTEDO®; Raises 2024 Financial Guidance
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
Wall Street Remains On Track For AMD-Led Rebound Ahead Of Fed Decision, Meta Earnings: Analyst Says 'The Bull Tends To Remain' Despite Near-Time Volatility
Via Benzinga
Topics Economy
Exposures Interest Rates
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Teva and Sanofi Announce Accelerated Timeline for Anti-TL1A Phase 2b Program in Patients with Inflammatory Bowel Disease
From Teva Pharmaceutical Industries Limited
Via Business Wire
Why Hims & Hers Heath Shares Are Surging Today
Via Benzinga
Teva's Migraine Treatment Found Effective For Children As Young As 6
Via Benzinga
Teva Announces First Phase 3 Evidence of Efficacy and Safety of an Anti-CGRP Monoclonal Antibody in Children in AJOVY® (fremanezumab) SPACE Trial for Prevention of Episodic Migraine
From Teva Pharmaceutical Industries Limited
Via Business Wire
Jim Cramer Says Don't Sell Match Group: 'You've Just Got A Very, Very Smart Investor In There'
Via Benzinga
3 No-Brainer Stocks to Buy With $200 Right Now
Via The Motley Fool
Here's How Much $1000 Invested In Teva Pharmaceutical Indus 5 Years Ago Would Be Worth Today
Via Benzinga
Teva Pharmaceuticals Stock: Unlock Value in This Generic Drug Gem
Via MarketBeat
Teva to Host Conference Call to Discuss Second Quarter 2024 Financial Results at 8 a.m. ET on July 31, 2024
From Teva Pharmaceutical Industries Limited
Via Business Wire
FTC Crackdown on Teva Pharmaceuticals Over Inhaler Patent Abuse
Via Benzinga
Topics Intellectual Property
Exposures Intellectual Property
Dr. Reddy's Labs Stock Sees Improved Technical Strength
Via Investor's Business Daily
New AJOVY® (fremanezumab) Migraine Prevention Data Challenges Treatment Pauses
From Teva Pharmaceutical Industries Limited
Via Business Wire
Teva Reaches Agreement With the Israel Tax Authority to Resolve All Pending Litigation for the Company's Taxable Years 2008-2020
From Teva Pharmaceutical Industries Limited
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.